Takeda is guided by the values of integrity, fairness, honesty and perseverance.
A COMPANY built on strong core values, Takeda is a research and development-driven global biopharmaceutical company guided by its values of ‘Takeda-ism’: integrity, fairness, honesty and perseverance.
Working towards creating better health for people and a brighter future for the world, the company’s mission is brought to life through its decision-making framework, based on the order of patient-trust-reputation-business.
Today, its business is driven by 14 global strategic growth brands in five business areas – oncology, rare disease, gastroenterology, neuroscience and plasma-derived therapies – with targeted research and development investment in vaccines.
Despite the harsh economic environments ensuing from the Covid-19 pandemic, Takeda has maintained its global strategy of prioritising sustainable approaches for constant business growth. This has enabled the company to continuously invest in the discovery, development and delivery of future innovative medicines in line with its ambition to grow ahead of the competing market. As a testament to Takeda’s commitment to employees’ wellbeing and growth, not only has Takeda Malaysia Sdn Bhd (Takeda Malaysia) received the Top Employer Certification for the sixth year in a row, this year they also recently received the highly coveted Great Place to Work accreditation for the first time in Malaysia, Singapore and Vietnam.
Adding to that, being awarded Brand Laureate ‘Brand of the Year: Prominent Business Best Brands’ in 2019 has motivated the company to constantly set new targets as it continues to work towards addressing the unmet medical needs of patients living with rare and complex diseases.
Crediting its success to an unwavering commitment to putting patients first and addressing unmet medical needs, Takeda focuses on highly innovative therapies and is committed to tackling the toughest problems in public health, such as dengue, to improve the lives of people in Malaysia and around the world.
Being patient-centric, Takeda is a trusted partner in delivering effective and innovative therapies, which are made accessible via sustainable programmes that provide access to medicines, as well as relevant services or support across diagnosis and treatment.
These include Early Access Programmes, innovative market access schemes, and Patient Assistance Programmes, from which close to 300 patients in Malaysia have benefited.
Gomes said that Takeda’s employees understand that everyone plays a fundamental role in making a positive impact on patients’ lives.
Recently appointed Takeda VMAPS (Vietnam, Malaysia, Philippines and Singapore) cluster head Igor Gomes shares on his extensive industry experience that led him around the world to his role today, “I’ve been in the pharmaceutical industry for over two decades, with 14 of it being with Takeda, and my earlier experience coming from other large multinational companies. I joined Takeda Brazil in 2008 and had the opportunity to work abroad in Dubai (Strategy and Business Support Director), Argentina (Business Operations Head), Ecuador, and Peru as a country manager. In June 2021, I relocated from Sao Paolo, Brazil to Kuala Lumpur, with my family, when I was appointed the VMAPS cluster head. My long tenure with Takeda is a testament to how its corporate aspirations are aligned with my personal aspirations.”
Aside from an alignment in aspirations, Gomes also embraces an alignment of values. “I lead with our framework of Patient-Trust-Reputation-Business, front and centre. Our employees understand that everyone plays an important role in making a positive impact on patients’ lives, saying “A fundamental question we ask ourselves every day is, “How can we do more for patients?” I believe that by doing things right, our business growth follows naturally.”
He added that to address the lack of access and the large underserved populations in the region and in Malaysia, the company is determined to help strengthen the local healthcare system by growing Takeda’s partnerships with its stakeholders.
He comments, “Among our key focus areas this year is to collaborate with different stakeholders to bring the focus back to the looming threat of dengue and to encourage the public to recognise the risk of dengue to one’s self and their families.
“Dengue has not been in the limelight enough due to Covid-19, but the threat of an outbreak remains and Malaysia is one of many dengue-endemic countries that has a high disease burden.”
In view of this, Takeda aims to transform this age-old infectious disease into a vaccine-preventable infectious disease by developing a live-attenuated tetravalent dengue vaccine candidate that has been submitted for regulatory approval in the EU and a number or dengue-endemic countries around the world.
Gomes and his team are ready for the challenges and opportunities that lay ahead saying, “Being appointed to my current role, I have gained valuable insights and exposure to the melting pot of cultures in this region. I am excited to be given this opportunity to grow Takeda’s presence in this cluster and deliver strong business growth in our five key therapy areas.”
With this, the company is upholding its purpose to create better health for people, brighter future for the world.
